Lupin has received approval from Health Canada for pegfilgrastim, a biosimilar to Amgen's Neulasta. This product will be marketed under the brand name Armlupeg and manufactured at Lupin’s Biotech ...

Stimufend ® (pegfilgrastim-fpgk), a biosimilar to Neulasta ® (pegfilgrastim), has been made available by Fresenius Kabi. Stimufend, a leukocyte growth factor, is indicated to decrease the incidence of ...

ZURICH, Nov 18 (Reuters) - The U.S. Food and Drug Administration has accepted Novartis unit Sandoz's submission for approval of a biosimilar version of U.S.-based Amgen's Neulasta drug that fights ...

Biocon and Mylan have announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Fulphila, a biosimilar ...

Biocon has acknowledged that the FDA has held off approving its application with Mylan to market a biosimilar version of Amgen’s Neulasta ® (pegfilgrastim) pending submission of additional data.